Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Transfusion. 2021 Feb;61(2):516-525. doi: 10.1111/trf.16198. Epub 2020 Nov 27.

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is a common indication for autologous stem cell transplantation (auto-SCT).

Study design and methods: This prospective noninterventional study aimed to evaluate the impact of mobilization characteristics and graft cellular content on hematologic recovery and outcome after auto-SCT among 68 patients with DLBCL.

Results: Better mobilization capacity as manifested by blood CD34+ cell count >32 × 106 /L and CD34+ cell yield of the first apheresis >2.75 × 106 /kg correlated with faster neutrophil (P = .005 and P = .017) and platelet (P = .002 and P < .001) recovery. A higher number of infused CD34+ cells (> 2.65 × 106 /kg) was associated with better 5-year overall survival (OS; 95% vs 67%, P = .012). The graft CD34+ CD133+ CD38- cell count >0.07 × 106 /kg was predictive of better 5-year OS (87% vs 63%; P = .008) and higher graft CD3+ cell count (>23.1 × 106 /kg) correlated also with better 5-year OS (80% vs 40%, P = .008). In multivariate analysis only disease status of CR I at auto-SCT was associated with better progression-free survival (P = .014) and OS (P = .039).

Conclusion: The mobilization capacity of CD34+ cells impacted on early hematologic recovery in patients with DLBCL after auto-SCT. Higher graft CD34+ cell count and both CD34+ CD133+ CD38- and CD3+ cells were also associated with better OS. The effect of optimal graft cellular composition on outcome in DLBCL should be evaluated in a randomized study.

Keywords: CD34+ cell mobilization; autograft cellular composition; diffuse large B-cell lymphoma; hematologic recovery; outcome.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antigens, CD34 / analysis
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blood Cell Count
  • CD3 Complex / analysis
  • Carmustine / administration & dosage
  • Carmustine / adverse effects
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Cytarabine / administration & dosage
  • Cytarabine / adverse effects
  • Disease-Free Survival
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Febrile Neutropenia / chemically induced
  • Female
  • Filgrastim / pharmacology
  • Follow-Up Studies
  • Graft Survival
  • Hematopoietic Stem Cell Mobilization* / methods
  • Hematopoietic Stem Cells / chemistry
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Male
  • Melphalan / administration & dosage
  • Melphalan / adverse effects
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation / methods*
  • Peripheral Blood Stem Cell Transplantation / statistics & numerical data
  • Polyethylene Glycols / pharmacology
  • Progression-Free Survival
  • Prospective Studies
  • Remission Induction
  • Transplantation, Autologous
  • Treatment Outcome
  • Young Adult

Substances

  • Antigens, CD34
  • CD3 Complex
  • Cytarabine
  • pegfilgrastim
  • Polyethylene Glycols
  • Etoposide
  • Cyclophosphamide
  • Filgrastim
  • Melphalan
  • Carmustine

Supplementary concepts

  • BAEC protocol
  • BEAM regimen